RU94028888A - Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция - Google Patents

Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция

Info

Publication number
RU94028888A
RU94028888A RU94028888/04A RU94028888A RU94028888A RU 94028888 A RU94028888 A RU 94028888A RU 94028888/04 A RU94028888/04 A RU 94028888/04A RU 94028888 A RU94028888 A RU 94028888A RU 94028888 A RU94028888 A RU 94028888A
Authority
RU
Russia
Prior art keywords
isomers
formula
salts
derivatives
synthesis
Prior art date
Application number
RU94028888/04A
Other languages
English (en)
Other versions
RU2116297C1 (ru
Inventor
Виллиам Кэпрес Бредлей
Us]
Майкель Даунинг Деннис
Карлос Джейн Хуан
Джозеф Джонсон Стифен
Джон III CVBC Виллиам
Дейвид Вайс Лоуренс
Райт Джонатан
Джюрген Вюстро Дейвид
Original Assignee
Варнер-Ламберт Компани (US)
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер-Ламберт Компани (US), Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани (US)
Publication of RU94028888A publication Critical patent/RU94028888A/ru
Application granted granted Critical
Publication of RU2116297C1 publication Critical patent/RU2116297C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Объектом изобретения являются производные 1,3-замещенного циклоалкена и циклоалкана формулы I, приведенной в описании, смесь их изомеров или отдельные изомеры, их гидраты и соли. Другим объектом изобретения является фармацевтическая композиция с допаминергетической, антипсихотической и антигипертенической активностями, содержащая фармацевтически приемлемый жидкий или твердый носитель и активное начало на основе соединения формулы I. Объектом изобретения является способ получения производных 1,3- замещенного циклоалкена формулы Iа, также приведенной в описании, или их солей, а также способ получения производных 1,3-замещенного циклоалкана формулы Iг или их солей, отличающийся тем, что соединение формулы IV подвергают взаимодействию с восстанавливающим агентом, и целевой продукт выделяют в свободном виде или в виде соли, при необходимости в виде смеси изомеров или отдельных изомеров.

Claims (1)

  1. Объектом изобретения являются производные 1,3-замещенного циклоалкена и циклоалкана формулы I, приведенной в описании, смесь их изомеров или отдельные изомеры, их гидраты и соли. Другим объектом изобретения является фармацевтическая композиция с допаминергетической, антипсихотической и антигипертенической активностями, содержащая фармацевтически приемлемый жидкий или твердый носитель и активное начало на основе соединения формулы I. Объектом изобретения является способ получения производных 1,3- замещенного циклоалкена формулы Iа, также приведенной в описании, или их солей, а также способ получения производных 1,3-замещенного циклоалкана формулы Iг или их солей, отличающийся тем, что соединение формулы IV подвергают взаимодействию с восстанавливающим агентом, и целевой продукт выделяют в свободном виде или в виде соли, при необходимости в виде смеси изомеров или отдельных изомеров.
RU94028888/04A 1991-11-20 1992-11-05 Производные 1,3-замещенного циклоалкена и циклоалкана в форме смеси изомеров или отдельных изомеров, или их гидраты, или соли RU2116297C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79520791A 1991-11-20 1991-11-20
US07/795,207 1991-11-20
US07/795.207 1991-11-20
US07/957,277 US5314896A (en) 1991-11-20 1992-10-15 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
US07/957,277 1992-10-15
US07/957.277 1992-10-15

Publications (2)

Publication Number Publication Date
RU94028888A true RU94028888A (ru) 1997-02-20
RU2116297C1 RU2116297C1 (ru) 1998-07-27

Family

ID=27121601

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94028888/04A RU2116297C1 (ru) 1991-11-20 1992-11-05 Производные 1,3-замещенного циклоалкена и циклоалкана в форме смеси изомеров или отдельных изомеров, или их гидраты, или соли

Country Status (20)

Country Link
US (2) US5314896A (ru)
EP (2) EP0545095A1 (ru)
JP (1) JP3193718B2 (ru)
KR (1) KR100234600B1 (ru)
AT (1) ATE206398T1 (ru)
AU (1) AU664872B2 (ru)
CA (1) CA2122911C (ru)
CZ (1) CZ284181B6 (ru)
DE (1) DE69232099T2 (ru)
DK (1) DK0613465T3 (ru)
ES (1) ES2165360T3 (ru)
FI (2) FI106259B (ru)
HU (1) HU218935B (ru)
NO (1) NO180632C (ru)
NZ (1) NZ245174A (ru)
PT (1) PT613465E (ru)
RU (1) RU2116297C1 (ru)
SG (1) SG46641A1 (ru)
SK (1) SK280812B6 (ru)
WO (1) WO1993010092A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401692A (en) * 1993-06-15 1995-03-28 Texas Instruments Incorporated Method for minimizing particle generation on a wafer surface during high pressure oxidation of silicon
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5468767A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antidepressant 3-(aminocycloalkenyl)-indole-5-nitrile derivatives
US5710277A (en) * 1994-09-12 1998-01-20 Warner-Lambert Company Process for R (+) 1,2,3,6-tetrahydro-4-phenyl-1- (3-phenyl-3-cyclohexen-1-yl)methyl!pyridine, a central nervous system agent
US5773616A (en) * 1995-02-15 1998-06-30 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
CA2213197C (en) * 1995-02-15 2001-08-07 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
CN1184478A (zh) * 1995-03-22 1998-06-10 大正制药株式会社 噻唑衍生物
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5602168A (en) * 1995-07-10 1997-02-11 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US5656632A (en) * 1995-06-05 1997-08-12 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US5633724A (en) * 1995-08-29 1997-05-27 Hewlett-Packard Company Evanescent scanning of biochemical array
GB9523462D0 (en) * 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
EP1068184B1 (en) * 1998-04-08 2002-09-04 Wyeth N-aryloxyethylamine derivatives for the treatment of depression
WO2000040579A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6245780B1 (en) * 1999-04-22 2001-06-12 American Home Products Corp Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
CA2379021C (en) 1999-08-23 2009-10-27 Solvay Pharmaceuticals B.V. New phenylpiperazines
US6780305B2 (en) * 2001-02-20 2004-08-24 Fuji Photo Film Co., Ltd. Method for producing support for planographic printing plate, support for planographic printing plate, and planographic printing plate precursor
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US20040197284A1 (en) 2003-04-04 2004-10-07 Frederic Auguste Cosmetic composition comprising a volatile fatty phase
UY28538A1 (es) 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
EP2102145A4 (en) 2006-12-21 2014-06-18 Abbott Lab PROCESS FOR THE PREPARATION AND ISOLATION OF INDIVIDUAL STEREOISOMERS OF 1-AMINO, 3-SUBSTITUTED PHENYLCYCLOPENTAN CARBOXYLATES
UY30829A1 (es) * 2006-12-21 2008-07-31 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597921A (en) * 1984-07-26 1986-07-01 Northern Telecom Limited Provision of plastic insulation upon an electrical conductor
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US4975445A (en) * 1989-12-06 1990-12-04 Warner-Lambert Company Substituted cyclohexenes as central nervous system agents
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5124332A (en) * 1991-01-28 1992-06-23 Warner-Lambert Company Substituted indoles as central nervous system agents

Also Published As

Publication number Publication date
EP0545095A1 (en) 1993-06-09
JPH07501075A (ja) 1995-02-02
AU3129193A (en) 1993-06-15
NO941884D0 (no) 1994-05-19
HU218935B (hu) 2001-01-29
CA2122911A1 (en) 1993-05-27
PT613465E (pt) 2002-03-28
DE69232099T2 (de) 2002-06-06
NO180632B (no) 1997-02-10
ATE206398T1 (de) 2001-10-15
HU9401468D0 (en) 1994-08-29
EP0613465B1 (en) 2001-10-04
SK280812B6 (sk) 2000-08-14
ES2165360T3 (es) 2002-03-16
CA2122911C (en) 2003-10-14
NO941884L (no) 1994-05-19
CZ116194A3 (en) 1994-11-16
EP0613465A1 (en) 1994-09-07
NZ245174A (en) 1995-09-26
RU2116297C1 (ru) 1998-07-27
SK56994A3 (en) 1995-02-08
FI980471A0 (fi) 1998-03-02
FI942310A0 (fi) 1994-05-18
CZ284181B6 (cs) 1998-09-16
WO1993010092A1 (en) 1993-05-27
FI106259B (fi) 2000-12-29
KR100234600B1 (ko) 1999-12-15
FI942310A (fi) 1994-07-15
FI107383B (fi) 2001-07-31
DE69232099D1 (de) 2001-11-08
FI980471A (fi) 1998-03-02
NO180632C (no) 1997-05-21
SG46641A1 (en) 1998-02-20
US5314896A (en) 1994-05-24
HUT70520A (en) 1995-10-30
US5409931A (en) 1995-04-25
JP3193718B2 (ja) 2001-07-30
AU664872B2 (en) 1995-12-07
DK0613465T3 (da) 2002-02-04

Similar Documents

Publication Publication Date Title
RU94028888A (ru) Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
RU95108332A (ru) Производные индола и их таутомерные формы, смеси их изомеров и фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозин-киназы активностью и способ торможения зависящего от протеин-тирозин-киназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
SE7614258L (sv) Forfarande for framstellning av kinazoloderivat
MX9804107A (es) Derivados de quinolina.
RU95114376A (ru) Нитроэфиры, обладающие фармакологической активностью, и способ их получения
RU94027576A (ru) Производные 1-бензолсульфонил-1,3-дигидро-индол-2-она, способ их получения и содержащие их фармацевтические композиции
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
EA200300103A1 (ru) НОВАЯ β КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
NO301542B1 (no) Nye pyrazin-derivater
DK96786D0 (da) Aminosyrederivater
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
HUT64318A (en) Process for production benzodpyrane derivativs and pharmaceutical preparations containing these compounds as effective substance
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
GB1415471A (en) Phenylethylamine derivatives
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
ATE9584T1 (de) Antibakterielle beta-lactam-verbindungen, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
RU94036769A (ru) Алкильные производные тразодона, способ их получения, промежуточные соединения и фармацевтическая композиция
ES473415A1 (es) Un procedimiento para la preparacion de derivados de tiena- micina
NO904708D0 (no) Fremgangsmaate for fremstilling av derivater av 2-(3-pyridyl)-2-tetrahydrotiopyrankarbotioamid-1-oksid-(1r-2r).
ES8304923A1 (es) Un procedimiento para la preparacion de un peptido.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20031106